Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.

@article{Blay2014RandomisedPI,
  title={Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.},
  author={Jean-Yves Blay and Michael G. Leahy and Binh Bui Nguyen and Shreyaskumar Patel and Peter Hohenberger and A. Guijarro Santoro and Arthur P. Staddon and Nicolas Penel and S Piperno-neumann and Andrew Eugene Hendifar and Pilar Lardelli and Antonio Nieto and Vicente Alfaro and Sant P. Chawla},
  journal={European journal of cancer},
  year={2014},
  volume={50 6},
  pages={
          1137-47
        }
}
AIM This randomised phase III trial evaluated first-line trabectedin versus doxorubicin-based chemotherapy (DXCT) in patients with advanced/metastatic translocation-related sarcomas (TRS). METHODS Patients were randomly assigned (1:1) to receive trabectedin 1.5mg/m2 24-h intravenous (i.v.) infusion every 3 weeks (q3wk) (Arm A), or doxorubicin 75 mg/m2 i.v., q3wk, or doxorubicin 60 mg/m2 i.v. plus ifosfamide (range, 6-9 g/m2) i.v. q3wk (Arm B). Progression-free survival (PFS) by independent… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 37 CITATIONS

Similar Papers

Loading similar papers…